Display options
Cite
Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2010;25(2):83-90doi: 10.1016/j.blre.2010.09.004.
Paganin, M., & Ferrando, A. (2011). Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood reviews, 25(2), 83-90. https://doi.org/10.1016/j.blre.2010.09.004
Paganin, Maddalena, and Ferrando, Adolfo. "Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia." Blood reviews vol. 25,2 (2011): 83-90. doi: https://doi.org/10.1016/j.blre.2010.09.004
Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011 Mar;25(2):83-90. doi: 10.1016/j.blre.2010.09.004. Epub 2010 Oct 20. PMID: 20965628; PMCID: PMC3033461.
Copy Download .nbib Format: NLM
Share it on

Blood Rev. 2011 Mar;25(2):83-90. doi: 10.1016/j.blre.2010.09.004. Epub 2010 Oct 20.

Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.

Blood reviews

Maddalena Paganin, Adolfo Ferrando

Affiliations

  1. Institute for Cancer Genetics, Columbia University, NY, USA.

PMID: 20965628 PMCID: PMC3033461 DOI: 10.1016/j.blre.2010.09.004

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor resulting from the malignant transformation of immature T-cell progenitors. Originally associated with a dismal prognosis, the outcome of T-ALL patients has improved remarkably over the last two decades as a result of the introduction of intensified chemotherapy protocols. However, these treatments are associated with significant acute and long-term toxicities, and the treatment of patients presenting with primary resistant disease or those relapsing after a transient response remains challenging. T-ALL is a genetically heterogeneous disease in which numerous chromosomal and genetic alterations cooperate to promote the aberrant proliferation and survival of leukemic lymphoblasts. However, the identification of activating mutations in the NOTCH1 gene in over 50% of T-ALL cases has come to define aberrant NOTCH signaling as a central player in this disease. Therefore, the NOTCH pathway represents an important potential therapeutic target. In this review, we will update our current understanding of the molecular basis of T-ALL, with a particular focus on the role of the NOTCH1 oncogene and the development of anti-NOTCH1 targeted therapies for the treatment of this disease.

Copyright © 2010 Elsevier Ltd. All rights reserved.

References

  1. Blood. 2009 Apr 23;113(17):3918-24 - PubMed
  2. J Clin Oncol. 1991 Sep;9(9):1570-4 - PubMed
  3. Leukemia. 2010 Dec;24(12):2023-31 - PubMed
  4. Cell. 1994 Jul 15;78(1):45-57 - PubMed
  5. Blood. 2007 Aug 15;110(4):1251-61 - PubMed
  6. Cancer Res. 2003 Sep 1;63(17):5329-34 - PubMed
  7. Annu Rev Pathol. 2008;3:587-613 - PubMed
  8. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 - PubMed
  9. J Exp Med. 1996 May 1;183(5):2283-91 - PubMed
  10. Science. 2004 Oct 8;306(5694):269-71 - PubMed
  11. Nat Genet. 2007 May;39(5):593-5 - PubMed
  12. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9 - PubMed
  13. EMBO J. 1990 Feb;9(2):415-24 - PubMed
  14. Leukemia. 2010 Feb;24(2):371-82 - PubMed
  15. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 - PubMed
  16. Leukemia. 2002 Nov;16(11):2205-12 - PubMed
  17. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 - PubMed
  18. Genes Chromosomes Cancer. 1995 Sep;14(1):76-84 - PubMed
  19. Blood. 2005 Jun 15;105(12):4849-52 - PubMed
  20. Cancer Res. 2009 Apr 1;69(7):3060-8 - PubMed
  21. Blood. 1992 Aug 15;80(4):1090-3 - PubMed
  22. Nat Med. 2009 Jan;15(1):50-8 - PubMed
  23. Leukemia. 2006 Jul;20(7):1279-87 - PubMed
  24. Blood. 2003 Jul 1;102(1):262-8 - PubMed
  25. Oncogene. 1991 Oct;6(10):1887-93 - PubMed
  26. J Exp Med. 2007 Aug 6;204(8):1813-24 - PubMed
  27. Blood. 2010 Feb 11;115(6):1175-84 - PubMed
  28. Haematologica. 2008 Apr;93(4):533-42 - PubMed
  29. Nature. 2009 Nov 12;462(7270):182-8 - PubMed
  30. Cancer Cell. 2010 Apr 13;17(4):400-11 - PubMed
  31. Oncogene. 2008 Oct 2;27(44):5833-44 - PubMed
  32. Blood. 1991 Nov 15;78(10):2780-4 - PubMed
  33. Semin Hematol. 2000 Oct;37(4):381-95 - PubMed
  34. J Exp Med. 1991 Oct 1;174(4):867-73 - PubMed
  35. Blood. 1996 Jun 1;87(11):4804-8 - PubMed
  36. J Exp Med. 2007 Aug 6;204(8):1825-35 - PubMed
  37. J Exp Med. 2007 Dec 24;204(13):3059-66 - PubMed
  38. CNS Drugs. 2006;20(5):351-72 - PubMed
  39. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):244-9 - PubMed
  40. Leukemia. 2005 Mar;19(3):358-66 - PubMed
  41. Blood. 2008 Apr 15;111(8):4322-8 - PubMed
  42. Cell. 1991 Aug 23;66(4):649-61 - PubMed
  43. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11416-20 - PubMed
  44. Haematologica. 2006 Mar;91(3):317-21 - PubMed
  45. Haematologica. 2006 Sep;91(9):1212-21 - PubMed
  46. Science. 1990 Dec 7;250(4986):1426-9 - PubMed
  47. J Exp Med. 2008 Apr 14;205(4):751-8 - PubMed
  48. Nat Immunol. 2005 Sep;6(9):881-8 - PubMed
  49. EMBO J. 2006 Jan 11;25(1):129-38 - PubMed
  50. Eur J Haematol. 2006 Jul;77(1):27-34 - PubMed
  51. Blood. 2009 Feb 19;113(8):1689-98 - PubMed
  52. Leukemia. 2006 Jan;20(1):82-6 - PubMed
  53. Cell Cycle. 2005 Oct;4(10):1356-9 - PubMed
  54. Mol Cell. 2000 Feb;5(2):207-16 - PubMed
  55. Blood. 1999 Sep 15;94(6):2072-9 - PubMed
  56. Blood. 2009 Apr 30;113(18):4381-90 - PubMed
  57. Annu Rev Neurosci. 2003;26:565-97 - PubMed
  58. Immunity. 1999 Sep;11(3):299-308 - PubMed
  59. Science. 1991 Jul 5;253(5015):79-82 - PubMed
  60. J Clin Oncol. 2009 Sep 10;27(26):4352-6 - PubMed
  61. Cancer Cell. 2003 Dec;4(6):451-61 - PubMed
  62. Cancer Genet Cytogenet. 1992 Nov;64(1):86-90 - PubMed
  63. Blood. 2003 Aug 1;102(3):1000-6 - PubMed
  64. Nat Genet. 2010 Apr;42(4):338-42 - PubMed
  65. Mol Cell Biol. 2006 Jun;26(12):4642-51 - PubMed
  66. Nat Genet. 2010 Jun;42(6):530-5 - PubMed
  67. Br J Haematol. 1989 May;72(1):36-9 - PubMed
  68. EMBO J. 1991 Oct;10(10):2905-10 - PubMed
  69. Mol Cell Biol. 1989 May;9(5):2124-32 - PubMed
  70. J Biol Chem. 2004 Jan 23;279(4):2937-44 - PubMed
  71. Genes Dev. 2002 Feb 1;16(3):295-300 - PubMed
  72. Nat Med. 2007 Jan;13(1):70-7 - PubMed
  73. Leukemia. 2010 Dec;24(12):2014-22 - PubMed
  74. Blood. 2006 Nov 15;108(10):3520-9 - PubMed
  75. Blood. 2007 Jul 1;110(1):278-86 - PubMed
  76. Blood. 2006 Aug 15;108(4):1151-7 - PubMed
  77. Br J Haematol. 2009 Apr;145(2):198-206 - PubMed
  78. Cancer Sci. 2006 Aug;97(8):729-36 - PubMed
  79. Cancer Cell. 2002 Feb;1(1):75-87 - PubMed
  80. Blood. 2009 Dec 10;114(25):5136-45 - PubMed
  81. Cancer Res. 2007 Oct 1;67(19):9006-12 - PubMed
  82. Mol Cell Biol. 2006 Nov;26(21):8022-31 - PubMed
  83. Blood. 2005 Jul 1;106(1):274-86 - PubMed
  84. Immunity. 1999 May;10(5):547-58 - PubMed
  85. Br J Haematol. 2000 Jun;109(4):788-93 - PubMed
  86. Nat Genet. 2004 Oct;36(10):1084-9 - PubMed
  87. Mol Cell Biol. 2009 Nov;29(21):5679-95 - PubMed
  88. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8900-4 - PubMed
  89. Leukemia. 2000 Jan;14(1):100-4 - PubMed
  90. Leukemia. 2010 Dec;24(12):2005-13 - PubMed
  91. Toxicol Sci. 2004 Nov;82(1):341-58 - PubMed
  92. J Exp Med. 2009 Apr 13;206(4):779-91 - PubMed
  93. Blood. 1994 Dec 15;84(12):4038-44 - PubMed
  94. Br J Pharmacol. 2009 Nov;158(5):1183-95 - PubMed
  95. Blood. 2009 Jun 11;113(24):6172-81 - PubMed
  96. Genes Dev. 2006 Aug 1;20(15):2096-109 - PubMed
  97. Blood. 1991 Dec 1;78(11):2996-3003 - PubMed
  98. J Clin Invest. 2008 Sep;118(9):3181-94 - PubMed
  99. Leuk Res. 1999 Feb;23(2):115-26 - PubMed
  100. Leukemia. 2009 Aug;23(8):1374-7 - PubMed
  101. J Exp Med. 2008 Oct 27;205(11):2507-13 - PubMed
  102. Genes Chromosomes Cancer. 1997 Dec;20(4):363-71 - PubMed
  103. Science. 2008 Sep 12;321(5895):1499-502 - PubMed
  104. Hematology Am Soc Hematol Educ Program. 2009;:353-61 - PubMed
  105. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5039-43 - PubMed
  106. Proc Natl Acad Sci U S A. 1986 May;83(10):3439-43 - PubMed
  107. Exp Cell Res. 2007 Aug 15;313(14):3141-52 - PubMed
  108. J Biol Chem. 2009 Nov 6;284(45):31018-27 - PubMed
  109. Nature. 2010 Apr 15;464(7291):1052-7 - PubMed
  110. Blood. 2008 May 1;111(9):4668-80 - PubMed
  111. Immunol Res. 2006;34(2):117-32 - PubMed
  112. Blood. 2009 Jul 30;114(5):1038-45 - PubMed
  113. Proc Natl Acad Sci U S A. 1989 Dec;86(24):10128-32 - PubMed
  114. Genes Dev. 1996 Aug 1;10(15):1930-44 - PubMed
  115. Cell. 1989 Jul 14;58(1):77-83 - PubMed
  116. Nat Med. 2007 Oct;13(10):1203-10 - PubMed
  117. Blood. 2008 Aug 1;112(3):733-40 - PubMed
  118. Dev Biol. 2000 Dec 15;228(2):151-65 - PubMed
  119. Immunity. 2002 Jun;16(6):869-79 - PubMed
  120. Bone Marrow Transplant. 1999 Mar;23(6):555-60 - PubMed
  121. PLoS One. 2010 Feb 08;5(2):e9094 - PubMed
  122. Nature. 2005 Jun 16;435(7044):959-63 - PubMed
  123. Genes Chromosomes Cancer. 1990 Jan;1(3):194-208 - PubMed
  124. N Engl J Med. 1994 Nov 10;331(19):1253-8 - PubMed
  125. Mol Cell. 2000 Feb;5(2):197-206 - PubMed
  126. Mol Cancer Ther. 2010 Jun;9(6):1618-28 - PubMed
  127. Cancer Genet Cytogenet. 1990 Oct 1;49(1):69-74 - PubMed
  128. EMBO Rep. 2008 Apr;9(4):377-83 - PubMed
  129. Science. 1986 May 16;232(4752):884-6 - PubMed
  130. N Engl J Med. 2004 Apr 8;350(15):1535-48 - PubMed
  131. Nat Immunol. 2007 May;8(5):451-6 - PubMed
  132. Int Immunol. 2002 Jun;14(6):637-45 - PubMed
  133. Nature. 1990 Mar 8;344(6262):158-60 - PubMed

Substances

MeSH terms

Publication Types

Grant support